WSJ
28 Oct 2026, 09:49 UTC · 3h ago
Impact · against what's priced in
Sandoz faces downward pressure on its valuation due to lowered 2026 revenue guidance and operational headwinds. Supply constraints in the high-margin biosimilar segment and regional weakness in Germany directly threaten EPS estimates.
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Sandoz issued a more cautious outlook on top-line growth for 2026.
Newshares dropped after the company issued
So whatLowered revenue expectations for FY2026 will likely lead analysts to revise EPS estimates downward.
More negative than 95% of claims this week
Sandoz is facing supply constraints for biosimilar drugs.
Continue reading
5 related stories
Newshares dropped after the company issued
So whatInability to meet demand in the high-margin biosimilar segment pressures overall margin expansion for the coming quarters.
More negative than 88% of claims this week
The company cited challenging market conditions in Germany.
Newshares dropped after the company issued
More negative than 71% of claims this week
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Invezz
1h ago
